Differences

This shows you the differences between two versions of the page.

--- endocrine:glp1:semaglutide [2026/02/13 00:16] – [Contraindications] andrew2393cns
+++ endocrine:glp1:semaglutide [2026/02/13 00:17] (current) – [Clinical Pearls] andrew2393cns
@@ Line 131: / Line 131: @@
 [[endocrine:glp1:exenatide|Exenatide]]:
-• Shorter acting
+  * • Shorter acting
-• Less weight loss
+  * • Less weight loss
 [[endocrine:glp1:liraglutide|Liraglutide]]:
-• Daily injection
+  * • Daily injection
-• Proven ASCVD benefit
+  * • Proven ASCVD benefit
 [[endocrine:glp1:dulaglutide|Dulaglutide]]:
-• Weekly injection
+  * • Weekly injection
-• Strong ASCVD benefit
+  * • Strong ASCVD benefit
 Semaglutide:
-• Strongest weight loss among GLP-1 RAs
+  * • Strongest weight loss among GLP-1 RAs
-• Strong ASCVD reduction
+  * • Strong ASCVD reduction
-• Available oral formulation
+  * • Available oral formulation
 --------------------------------------------------------------------
@@ Line 153: / Line 153: @@
 Semaglutide:
-• Strong ASCVD reduction
+  * • Strong ASCVD reduction
-• Weight loss dominant
+  * • Weight loss dominant
 [[endocrine:sglt2:start|SGLT2 Inhibitors]]:
-• Strong heart failure benefit
+  * • Strong heart failure benefit
-• Strong renal protection
+  * • Strong renal protection
 These classes are often combined in cardiometabolic patients.
@@ Line 167: / Line 167: @@
 ===== Clinical Pearls =====
-✔ Weekly or oral option
+  * ✔ Weekly or oral option
-✔ Powerful weight loss
+  * ✔ Powerful weight loss
-✔ Reduces ASCVD events
+  * ✔ Reduces ASCVD events
-✔ Low hypoglycemia risk
+  * ✔ Low hypoglycemia risk
-✔ Not a core heart failure therapy
+  * ✔ Not a core heart failure therapy
-✔ Monitor for GI intolerance
+  * ✔ Monitor for GI intolerance
 --------------------------------------------------------------------